Nanobiotix stock lags behind despite +355% over one year

A decline that brings the stock below its two short-term moving averages

Nanobiotix loses 2.21% to €32.76 during the session, while the SBF 120 advances by 0.05% and the CAC 40 rises by a whisper (+0.09%). The stock thus finds itself below its 20-day MA at €34.98 (gap of -6.35%) and below its 50-day MA at €34.19 (gap of -4.18%), two moving averages that act as nearby resistance levels. This configuration, already noted during previous sessions, illustrates the pressure weighing on the stock over several sessions.

The RSI at 51 remains in neutral territory, without oversold signal despite the recent correction. The price is approaching the support level at €32.30, less than half a point below current levels. If this level holds, this threshold will represent the closest technical floor to monitor over the coming hours.

A weekly decline of nearly 10% that contrasts with an annual surge of 355%

With a decline of 9.65% over the week, the stock ranks among the largest drops in the SBF 120 at mid-session on this Monday, in an index with 120 members. The weekly correction contrasts with an annual performance of +355%, which places the biotech among the most dynamic securities on the French market over twelve months. Over one month, the decline remains limited to 1.33%, which indicates consolidation rather than a prolonged trend reversal.

For context, the stock's volatility has been marked for several weeks, with significant oscillations in both directions. Analysts' views on the security remain a point to follow in the coming weeks, in a context of global market tension, between expectations of rising US rates and a geopolitical risk premium linked to tensions in the Strait of Hormuz. The support level at €32.30 constitutes the key level to monitor at the end of this session.